

CITATION REPORT

List of articles citing

Novel Diabetes Drugs and the Cardiovascular Specialist

DOI: 10.1016/j.jacc.2017.04.014

Journal of the American College of Cardiology, 2017, 69, 2646-

Source: <https://exaly.com/paper-pdf/66454949/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
73	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016 , 118, 1830-43	15.7	46
72	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 704-712	15.1	106
71	Association between polymorphisms in the APOB gene and hyperlipidemia in the Chinese Yugur population. <i>Brazilian Journal of Medical and Biological Research</i> , 2017 , 50, e6613	2.8	10
70	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <i>Journal of the Chinese Medical Association</i> , 2018 , 81, 189-222	2.8	14
69	Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 213-222	3.9	32
68	Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1395-1400	0.9	21
67	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	79
66	Editor-in-Chief's Top Picks From 2017. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 890-934	15.1	
65	"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 448-459	5	15
64	Recent Approaches to Improve Medication Adherence in Patients with Coronary Heart Disease: Progress Towards a Learning Healthcare System. <i>Current Atherosclerosis Reports</i> , 2018 , 20, 5	6	16
63	Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	66
62	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. <i>Heart Failure Reviews</i> , 2018 , 23, 445-459	5	4
61	Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2018 , 6, 1-7	7.9	51
60	Which place of pharmacological approaches beyond continuous positive airway pressure to treat vascular disease related to obstructive sleep apnea?. <i>Pharmacology & Therapeutics</i> , 2018 , 186, 45-59	13.9	5
59	Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2131-2139	6.7	9
58	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1379-1390	15.1	43
57	Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 481-497	5	2

56	Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era. <i>Cardiovascular Endocrinology and Metabolism</i> , 2018 , 7, 2-3	2.5	4
55	The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1287-1302	5.5	41
54	Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs. <i>IJC Heart and Vasculature</i> , 2018 , 21, 80-86	2.4	2
53	The Intersection of Diabetes and Cardiovascular Disease-A Focus on New Therapies. <i>Frontiers in Cardiovascular Medicine</i> , 2018 , 5, 160	5.4	4
52	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3370-3372	15.1	61
51	The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1856-1869	15.1	43
50	Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain. <i>Diabetic Medicine</i> , 2018 , 35, 1605-1612	3.5	5
49	Evolution of Glucose-Lowering Drugs for Type 2 Diabetes. 2018 , 431-454		2
48	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2711-2723	6.7	16
47	Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials. <i>Cardiovascular Diabetology</i> , 2018 , 17, 85	8.7	15
46	The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	40
45	Cardiovascular outcome trials of the newer anti-diabetic medications. <i>Progress in Cardiovascular Diseases</i> , 2019 , 62, 342-348	8.5	16
44	Effect of Diabetes Mellitus on Complication Rates of Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2019 , 124, 1389-1396	3	5
43	Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. <i>Diabetes Care</i> , 2019 , 42, 2032-2041	14.6	5
42	Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction (the DIASTOLIC study). <i>BMJ Open</i> , 2019 , 9, e023207	3	8
41	Nine contemporary therapeutic directions in heart failure. <i>Heart Asia</i> , 2019 , 11, e011150	1.9	1
40	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019 , 10, 2042018819834869	4.5	39
39	Cardiovascular Protection with Anti-hyperglycemic Agents. <i>American Journal of Cardiovascular Drugs</i> , 2019 , 19, 249-257	4	13

38	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2022-2031	16.7	345
37	Cardiometabolic medicine: time to recognize a new clinical specialty?. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019 , 8, 47-48	2.5	5
36	Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2019 , 38, 721-735	0	1
35	Bringing the novel to the everyday. <i>British Journal of Cardiac Nursing</i> , 2019 , 14, 1-2	0.2	
34	Type 1 diabetes mellitus and coronary revascularization. <i>Cardiovascular Endocrinology and Metabolism</i> , 2019 , 8, 35-38	2.5	2
33	Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease. <i>Revista Portuguesa De Cardiologia</i> , 2019 , 38, 721-735	1	0
32	Reducing Cardiovascular Risk in Diabetes: Insights from Diabetes Trials. <i>Frontiers in Diabetes</i> , 2019 , 119-130		
31	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019 , 40, 2907-2919	9.5	22
30	Emerging glucose-lowering therapies: a guide for cardiologists. <i>Heart</i> , 2020 , 106, 18-23	5.1	6
29	Weighing Coronary Revascularization Options in Patients With Type 2 Diabetes Mellitus. <i>Canadian Journal of Diabetes</i> , 2020 , 44, 78-85	2.1	2
28	Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria. <i>Diabetic Medicine</i> , 2020 , 37, 44-52	3.5	3
27	A Stepwise Approach to the Management of Heart Failure and its Comorbidities. <i>Journal of Osteopathic Medicine</i> , 2020 , 120, 90-99	0.8	0
26	Cardiometabolic Medicine: Development of a New Subspecialty. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	6
25	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <i>Journal of the Chinese Medical Association</i> , 2020 , 83, 587-621	2.8	3
24	Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1307, 129-152	3.6	13
23	Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 520-529	6.7	7
22	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. <i>Heart</i> , 2022 , 108, 16-21	5.1	0
21	Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1843-1850	6.7	4

20	Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus. <i>Obesity Medicine</i> , 2021 , 23, 100329	2.6	1
19	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , 2021 , 1	5	2
18	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. <i>International Journal of Cardiology</i> , 2021 , 338, 248-257	3.2	0
17	Stimulus-cleavable chemistry in the field of controlled drug delivery. <i>Chemical Society Reviews</i> , 2021 , 50, 4872-4931	58.5	22
16	Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. <i>Current Pharmaceutical Design</i> , 2020 , 26, 5911-5932	3.3	1
15	Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. <i>World Journal of Diabetes</i> , 2019 , 10, 490-510	4.7	34
14	Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. <i>EuroIntervention</i> , 2018 , 14, e1049-e1056	3.1	29
13	LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIABETES: A MANDATE FOR CARDIOLOGIST AND INTERNIST. <i>Russian Journal of Cardiology</i> , 2018 , 89-92	1.3	
12	Diabetes is still a CAD risk equivalent, now what?. <i>Journal of Nuclear Cardiology</i> , 2021 , 1	2.1	0
11	Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.. <i>PLoS ONE</i> , 2022 , 17, e0267025	3.7	0
10	Nanoformulations of flavonoids for diabetes and microvascular diabetic complications. <i>Drug Delivery and Translational Research</i> ,	6.2	1
9	Vascular disease prevention and management after cancer therapy. 2023 , 264-270		
8	Effect of Glucagon-like Peptide 1 Receptor Agonists on the Renal Protection in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>Diabetes and Metabolism</i> , 2022 , 101366	5.4	0
7	DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. 2022 , 9,		0
6	Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study. 2022 , 21,		1
5	Prevalence of cardiovascular events among patients with type 2 diabetes in the west region of Saudi Arabia. 2022 ,		0
4	Using similar patients to predict complication in patients with diabetes, hypertension, and lipid disorder: a domain knowledge-infused convolutional neural network approach.		1
3	New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. 2023 , 337-349		0

- 2 Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. **2023**, 43, 1-7 ○
- 1 Stimuli-Responsive Boron-Based Materials in Drug Delivery. **2023**, 24, 2757 ○